JCIC Asset Management Inc. Invests $2 Million in Novo Nordisk A/S $NVO

JCIC Asset Management Inc. acquired a new stake in Novo Nordisk A/S (NYSE:NVO) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 36,099 shares of the company’s stock, valued at approximately $2,003,000.

Other institutional investors have also added to or reduced their stakes in the company. True Wealth Design LLC lifted its stake in Novo Nordisk A/S by 209.8% in the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock valued at $25,000 after acquiring an additional 300 shares during the last quarter. NewSquare Capital LLC lifted its stake in Novo Nordisk A/S by 174.1% in the 2nd quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock valued at $31,000 after purchasing an additional 282 shares during the last quarter. Mid American Wealth Advisory Group Inc. bought a new position in Novo Nordisk A/S during the second quarter worth about $37,000. Maseco LLP acquired a new position in Novo Nordisk A/S during the second quarter worth approximately $39,000. Finally, Steigerwald Gordon & Koch Inc. acquired a new position in Novo Nordisk A/S during the third quarter worth approximately $39,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Early U.S. launch showed encouraging demand — oral Wegovy recorded 3,071 prescriptions in the first four days after launch, a datapoint traders flagged as a strong initial uptake. Read More.
• Positive Sentiment: Analyst notes described the rollout as a “solid start,” supporting upside expectations while emphasizing the need for more data to gauge sustained demand. Read More.
• Positive Sentiment: U.K. regulator approved a higher Wegovy dose (up to 7.2 mg weekly), expanding label flexibility and the addressable market for higher‑intensity treatment. Read More.
• Neutral Sentiment: Some analysts caution early prescription figures may not fully reflect long‑term demand or uptake dynamics; UBS warned initial data can be misleading even while it lifted its price target. Read More.
• Neutral Sentiment: High trading volume and elevated market attention increase short‑term volatility as investors parse launch metrics, regulation and competitor actions. Read More.
• Negative Sentiment: Legal risk: a compounding pharmacy has sued Novo (and Eli Lilly) over GLP‑1 access, alleging antitrust issues — a development prompting near‑term share pressure and regulatory/legal expense risk. Read More.
• Negative Sentiment: Valuation concerns persist: commentary argues Novo’s current valuation may not fully justify bullishness if growth or pricing faces headwinds, a viewpoint that can temper upside. Read More.

Novo Nordisk A/S Trading Up 9.1%

Shares of Novo Nordisk A/S stock opened at $62.32 on Monday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.57 and a current ratio of 0.78. The firm has a 50-day moving average of $50.85 and a 200-day moving average of $54.87. Novo Nordisk A/S has a 52-week low of $43.08 and a 52-week high of $93.80. The stock has a market cap of $278.26 billion, a PE ratio of 18.12 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.25. The business had revenue of $11.79 billion during the quarter, compared to analysts’ expectations of $11.98 billion. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. As a group, sell-side analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Analyst Ratings Changes

NVO has been the subject of a number of recent analyst reports. Zacks Research raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, January 9th. HSBC reaffirmed a “hold” rating and set a $54.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, December 10th. CICC Research assumed coverage on shares of Novo Nordisk A/S in a research report on Friday, January 9th. They issued an “outperform” rating and a $73.50 price objective on the stock. The Goldman Sachs Group cut their target price on shares of Novo Nordisk A/S from $60.00 to $54.00 and set a “buy” rating for the company in a research note on Friday, November 28th. Finally, Hsbc Global Res lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 24th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Novo Nordisk A/S presently has an average rating of “Hold” and an average price target of $56.21.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.